APT raises $32.3 million for inhaled cyclosporine trial
This article was originally published in Scrip
APT Pharmaceuticals has completed a $32.3 million series B financing round for its serious lung disease programmes. The US speciality drug development company will complete a pivotal Phase III trial evaluating the safety and efficacy of Pulminiq (inhalable cyclosporine), a lung transplant rejection treatment, and to develop its other pipeline programmes. Dr Stephen Dilly, APT president and CEO, said that the money would enable the company to bring inhaled cyclosporine to market and to become a profitable company. It raised $22 million last year for the development of Pulminiq (Scrip Online, October 8th, 2008). The latest financing included Three Arch Partners, InterWest Partners and Pinnacle Ventures. Bill Harrington has joined the APT board of directors, while Nina Kjellson of InterWest and David Kim of Pinnacle have become board observers.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.